PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Drospirenone - Menopausal disorders

PAD Profile : Drospirenone - Menopausal disorders

Brand Names Include :
Slynd

Traffic Light Status

Status 1 of 1.

Status :
N/A
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Un
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

Surrey contraceptive guidelines can be found here: https://surreyccg.res-systems.net/PAD/Guidelines/Detail/6303

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.03.02. Progestogen-only contraceptives
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More